These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 27441574)

  • 1. The limited benefit of "product-by-process" claim.
    Chang BC; Wang SJ
    Hum Vaccin Immunother; 2016 Oct; 12(10):2685-2687. PubMed ID: 27441574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design-around biotechnology patents: an analysis of US Federal Circuit decisions shows the possibility of designing around biotechnology patents.
    Wang SJ
    Hum Vaccin; 2011 Jan; 7(1):125-8. PubMed ID: 21263222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The written description rejection as a barrier to biotech patent prosecution.
    Wang SJ
    Hum Vaccin; 2011 May; 7(5):569-73. PubMed ID: 21552000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sharpening a biotech patent through methods claims under the litigation strategy of induced infringement: a message from the US Federal Circuit full court decision.
    Wang SJ
    Hum Vaccin Immunother; 2014; 10(3):808-11. PubMed ID: 24366057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using the written description requirement to limit broad patent scope, allow competition, and encourage innovation in biotechnology.
    Mull WC
    Health Matrix Clevel; 2004; 14(2):393-435. PubMed ID: 15503695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drafting eligible biotech and immunotherapy claims.
    Wang SJ
    Hum Vaccin Immunother; 2019; 15(11):2706-2712. PubMed ID: 30991887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The obviousness rejection as a barrier to vaccine patent prosecution.
    Wang SJ
    Hum Vaccin; 2011 Apr; 7(4):474-6. PubMed ID: 21808149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The shadow of inequitable conduct in the US patent application.
    Chang BC; Wang SJ
    Hum Vaccin Immunother; 2016 May; 12(5):1318-20. PubMed ID: 26810884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Competition policy in patent cases and antitrust.
    Sobel G
    Adv Genet; 2003; 50():23-64; discussion 507-10. PubMed ID: 14714685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patentability and maximum protection of intellectual property in proteomics and genomics.
    Warburg RJ; Wellman A; Buck TB; Ligler Schoenhard A
    Pharmacogenomics; 2003 Jan; 4(1):81-90. PubMed ID: 12517288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Divided Infringement in the Limelight of the Patent Battle Field.
    Chen FC
    Trends Biotechnol; 2016 Oct; 34(10):771-773. PubMed ID: 27262507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of the factors that result in obviousness rulings for biotech patents: an updated analysis of the US Federal Circuit decisions after KSR.
    Lin F; Wang SJ
    Hum Vaccin Immunother; 2013 Nov; 9(11):2490-5. PubMed ID: 23899509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The challenges of joint performance to method patents.
    Chen FC
    Expert Opin Ther Pat; 2017 Apr; 27(4):393-399. PubMed ID: 28266880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metastasizing patent claims on BRCA1.
    Kepler TB; Crossman C; Cook-Deegan R
    Genomics; 2010 May; 95(5):312-4. PubMed ID: 20226239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patent first, ask questions later: morality and biotechnology in patent law.
    Bagley MA
    William Mary Law Rev; 2003 Dec; 45(2):469-547. PubMed ID: 15570677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patent filing strategies: perspectives from the Cooperation Council for the Arab States of the Gulf.
    Koshy NJ
    Pharm Pat Anal; 2016 Jul; 5(4):217-26. PubMed ID: 27391111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patent infringement. Court denies motion to alter patent claim decision.
    AIDS Policy Law; 2003 Dec; 18(22):6. PubMed ID: 14974399
    [No Abstract]   [Full Text] [Related]  

  • 18. Life forms protectable as subjects of US patents--microbes to animals (perhaps).
    Hodgins DS
    Appl Biochem Biotechnol; 1987; 16():79-93. PubMed ID: 3504131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ethical reasons for narrowing the scope of biotech patents.
    Andreassen T
    Med Health Care Philos; 2015 Nov; 18(4):463-73. PubMed ID: 25968142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inventions in biotechnology and the assessment of obviousness.
    Finney K
    Australas Biotechnol; 1994; 4(5):280-3. PubMed ID: 7765674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.